TS 032

Drug Profile

TS 032

Alternative Names: PF-04802540; PF-4802540; TS-032

Latest Information Update: 28 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Pfizer; Taisho Pharmaceutical
  • Class Antipsychotics
  • Mechanism of Action Metabotropic glutamate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 27 Jan 2010 Discontinued - Phase-I for Schizophrenia in Singapore (PO)
  • 27 Jan 2010 Discontinued - Preclinical for Schizophrenia in Japan (PO)
  • 09 Oct 2008 Phase-I clinical trials in Schizophrenia in Singapore (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top